Skip to main content
SpringerLink
Log in

Medications Commonly Used in Pediatric HSCT

  • Chapter
  • First Online:
Hematopoietic Stem Cell Transplantation for the Pediatric Hematologist/Oncologist

  • 1215 Accesses

Abstract

This chapter contains charts of medication classes most commonly used in pediatric hematopoietic stem cell transplantation (HSCT). These include chemotherapeutics, immunosuppressants, SOS/VOD medications, antibacterials, antifungals, antivirals, anti-pneumocystis agents, pain medications, and diuretics. This chapter is designed to be a quick reference guide, and thus the detailed references provided should be consulted for more complete information. While the dosing provided is pediatric-based, more comprehensive references should be reviewed for neonatal/young infant dosing.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Similar content being viewed by others

Bibliography

  1. Lexicomp online® Pediatric & Neonatal Lexi-Drugs®, Hudson, OH: Lexi-Comp Inc; 2017.

    Google Scholar 

  2. Busulfex (busulfan) prescribing information. Rockville, MD: Otsuka America Pharmaceutical, Inc.; 2016.

    Google Scholar 

  3. Chabner BA, Bertino J, Cleary J, Ortiz T, Lane A, Supko JG, Ryan D. Cytotoxic agents. In: Brunton LL, Chabner BA, Knollmann BC, editors. Goodman & Gilman’s the pharmacological basis of therapeutics. 12th ed. New York, NY: McGraw-Hill; 2011. http://accesspharmacy.mhmedical.com/content.aspx?bookid=374&Sectionid=41266273. Accessed 8 Mar 2016.

    Google Scholar 

  4. Gerson SL, Bulgar AD, Weeks LD, Chabner BA. Alkylating agents. In: Chabner BA, Long DL, editors. Cancer chemotherapy and biotherapy: principles and practice. 5th ed. New York, NY: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2011. http://ovidsp.tx.ovid.com.proxy.library.vanderbilt.edu/sp-3.18.0b. Accessed 4 Mar 2016.

    Google Scholar 

  5. Nieto Y, Vaughan WP. Pharmacokinetics of high-dose chemotherapy. Blood Marrow Transplant. 2004;33:259–69.

    Article  CAS  Google Scholar 

  6. Ciurea SO, Andersson BS. Busulfan in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2009;15(5):523–36.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Kashyap A, Wingard J, Cagnoni P, et al. Intravenous versus oral busulfan as part of a busulfan/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: decreased incidence of hepatic venoocclusive disease (HVOD), HVOD-related mortality, and overall 100-day mortality. Biol Blood Marrow Transplant. 2002;8:493–500.

    Article  CAS  PubMed  Google Scholar 

  8. Grochow LB, Krivit W, Whitley CB, et al. Busulfan disposition in children. Blood. 1990;75:1723–1727. (220).

    Google Scholar 

  9. Vassal G, Fischer A, Challine D, et al. Busulfan disposition below the age of three: alteration in children with lysosomal storage disease. Blood. 1993;82:1030–4.

    CAS  PubMed  Google Scholar 

  10. Bartelink IH, Bredius RG, Ververs TT, et al. Once-daily intravenous busulfan with therapeutic drug monitoring compared to conventional oral busulfan improves survival and engraftment in children undergoing allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2008;14:88–98.

    Article  CAS  PubMed  Google Scholar 

  11. Hassan M, Ehrsson H, Smedmyr B, et al. Cerebrospinal fluid and plasma concentrations of busulfan during high-dose therapy. Bone Marrow Transplant. 1989;4:113–4.

    CAS  PubMed  Google Scholar 

  12. Hassan M, Oberg G, Bjorkholm M, et al. Influence of prophylactic anticonvulsant therapy on high-dose busulphan kinetics. Cancer Chemother Pharmacol. 1993;33(3):181–6.

    Article  CAS  PubMed  Google Scholar 

  13. Slattery JT, Sanders JE, Buckner CD, et al. Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics. Bone Marrow Transplant. 1995;16:31–42.

    CAS  PubMed  Google Scholar 

  14. Kletzel M, Jacobsohn D, Duerst R. Pharmacokinetics of a test dose of intravenous busulfan guide dose modifications to achieve an optimal area under the curve of a single daily dose of intravenous conditioning regimen with hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2006;12:472–9.

    Article  CAS  PubMed  Google Scholar 

  15. Russell JA, Kangarloo SB. Therapeutic drug monitoring of busulfan in transplantation. Curr Pharm Des. 2008;14:1936–49.

    Article  CAS  PubMed  Google Scholar 

  16. Almog S, Kurnik D, Shimoni A, et al. Linearity and stability of intravenous busulfan pharmacokinetics and the role of glutathione in busulfan elimination. Biol Blood Marrow Transplant. 2011;17(1):117–23.

    Article  CAS  PubMed  Google Scholar 

  17. Buggia I, Zecca M, Alessandrino EP, et al. Itraconazole can increase systemic exposure to busulfan in patients given bone marrow transplantation. GITMO (Gruppo Italiano Trapianto di Midollo Osseo). Anticancer Res. 1996;16(4A):2083–8.

    CAS  PubMed  Google Scholar 

  18. Nilsson C, Aschan J, Hentschke P, et al. The effect of metronidazole on busulfan pharmacokinetics in patients undergoing hematopoietic stem cell transplantation. Bone Marrow Transplant. 2003;31(6):429–35.

    Article  CAS  PubMed  Google Scholar 

  19. Khandelwal P, et al. A prospective study of alemtuzumab as a second-ling agent for steroid-refractory acute graft-versus-host-disease in pediatric and young adult allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2016:2220–5.

    Google Scholar 

  20. Gomez-Almaguer D, et al. Alemtuzumab for the treatment of steroid refractory acute graft-versus-host disease. Blood Marrow Transplant. 2008;14:10–5.

    Article  CAS  Google Scholar 

  21. Call S, et al. Total and active rabbit antithymocyte globulin pharmacokinetics in pediatric patients undergoing unrelated donor bone marrow transplantation. Biol Blood Marrow Transplant. 2009;15:274–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Takashima S, et al. The use of oral beclomethasone dipropionate in the treatment of gastrointestinal graft-versus-hose disease: the experience of the Fukuoka Blood and Marrow Transplantation Group. Intern Med. 2014;53:1315–20.

    Article  CAS  PubMed  Google Scholar 

  23. Hockenbery D, et al. A randomized, placebo-controlled trial of oral beclomethasone dipropionate as a prednisone-sparing therapy for gastrointestinal graft versus-host-disease. Blood. 2007;109:4557–63.

    Article  CAS  PubMed  Google Scholar 

  24. Diez-Campelo M, Perez-Simon JA, Castilla C, et al. Oral beclomethasone dipropionate for the treatment of GI acute graft versus host disease. Biol Blood Bone Marrow Transplant. 2006;12(Feb):36.

    Article  Google Scholar 

  25. Andree H, et al. Enteral budesonide in treatment for mild and moderate gastrointestinal chronic GVHD. Bone Marrow Transplant. 2008;42:541–6.

    Article  CAS  PubMed  Google Scholar 

  26. Elad S, et al. Budesonide: a novel treatment for oral chronic graft versus host disease. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2003;95:308–11.

    Article  PubMed  Google Scholar 

  27. Gonzalez-Moles MA, et al. Treatment of severe chronic oral erosive lesions with clobetasol propionate in aqueous solution. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2002;93:264–70.

    Article  PubMed  Google Scholar 

  28. Noce C, et al. Randomized double-blind clinical trial comparing clobetasol and dexamethasone for the topical treatment of symptomatic oral chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2014;20:1163–8.

    Article  CAS  PubMed  Google Scholar 

  29. Triester N, et al. How we treat oral chronic graft-versus-host disease. Blood. 2012;25:3407–18.

    Article  Google Scholar 

  30. Yanik G, et al. Tacrolimus and methotrexate as prophylaxis for acute graft-versus-host disease in pediatric allogenic stem cell transplantation. Bone Marrow Transplant. 2000;26:161–7.

    Article  CAS  PubMed  Google Scholar 

  31. Skeens M, et al. Twice daily IV bolus tacrolimus infusion for GVHD prophylaxis in children undergoing stem cell transplantation. Bone Marrow Transplant. 2012:1–4.

    Google Scholar 

  32. McCune JS, Bemer MJ, Long-Boyle J. Pharmacokinetics, pharmacodynamics and pharmacogenomics of immunosuppressants in allogenic hematopoietic cell transplantation: part II. Clin Pharmacokinet. 2016;55(5):551–93.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Yang J, Ceuk DK, Ha SY, et al. Infliximab for steroid refractory or dependent gastrointestinal acute graft-versus-host disease in children after allogeneic hematopoietic stem cell transplantation. Pediatr Transplant. 2012;16(7):771–8.

    Article  CAS  PubMed  Google Scholar 

  34. Kharfan-Dabaja M, Cutler C. Rituximab for prevention and treatment of graft-versus-host disease. Int J Hematol. 2012;93(5):578–85.

    Article  Google Scholar 

  35. Wolff D, Scheluning M, von Harsorf S, et al. Consensus conference on clinical practice in chronic gvhd: second line treatment of chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2011;17(1):1–17.

    Article  PubMed  Google Scholar 

  36. Gatza E, Braun T, Levine JE, et al. Etanercept plus topical corticosteroids as initial therapy for grade one acute graft versus host disease after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2014;20(9):1426–34.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Wang JZ, Liu LPXLP, et al. Basiliximab for the treatment of steroid refractory acute graft-versus host disease after unmanipulated HLA-mismatched/haploidentical hematopoietic stem cell transplantation. Tranplant Proc. 2011:1928–33.

    Google Scholar 

  38. Wang Z, Zheng X, Yan H, et al. Good outcome of haploidentical hematopoietic SCT as a salvage therapy in children and adolescents with acquired severe aplastic anemia. Bone Marrow Transplant. 2014;49(12):1481–5.

    Article  CAS  PubMed  Google Scholar 

  39. Kulkarni S, Powles R, Sirohi B, et al. Thalidomide after allogeneic haematopoietic stem cell transplantation: activity in chronic but not in acute graft-versus-host disease. Bone Marrow Transplant. 2003;32(2):165–70.

    Article  CAS  PubMed  Google Scholar 

  40. Browne PV, Weisdorf DJ, DeFor T, et al. Response to thalidomide therapy in refractory chronic graft-versus-host disease. Bone Marrow Transplant. 2000;26(8):865–9.

    Article  CAS  PubMed  Google Scholar 

  41. Defibrotide (Defitelio®) prescribing information. Palo Alto, CA: Jazz Pharmaceuticals; 2016.

    Google Scholar 

  42. Essell JH, Thompson JM, Harman GS, et al. Pilot trial of prophylactic ursodiol to decrease the incidence of veno-occlusive disease of the liver in allogeneic bone marrow transplant patients. Bone Marrow Transplant. 1992;10(4):367–72.

    CAS  PubMed  Google Scholar 

  43. American Academy of Pediatrics, Committee on Infectious Diseases. Red book. Elk Grove Village, IL: American Academy of Pediatrics, Committee on Infectious Diseases; 2015.

    Google Scholar 

  44. Hafez HA, et al. Prophylactic levofloxacin in pediatric neutropenic patient during autologous hematopoietic stem cell transplantation. Clin Transpl. 2015;29:1112–8.

    Article  CAS  Google Scholar 

  45. Choeyprasert W, et al. Bacteremia during neutropenic episodes in children undergoing hematopoietic stem cell transplantation with ciprofloxacin and penicillin prophylaxis. Int J Hematol. 2016;

    Google Scholar 

  46. Cecinati V, et al. Antibiotic prophylaxis in children with cancer or who have undergone hematopoietic cell transplantation. Eur J Clin Microbiol Infect Dis. 2014;22:1–6.

    Article  Google Scholar 

  47. Tomblyn M, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant. 2009;15:1143–238.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Bradley JS, Nelson JD, Barnett E, et al. Nelson's pediatric antimicrobial therapy. 22nd ed. American Academy of Pediatrics: Elk Grove Village, IL; 2016.

    Google Scholar 

  49. Johnson C. Dialysis of drugs. Verona, WI: CKD Insights, LLC; 2010.

    Google Scholar 

  50. Fluconazole (Diflucan®) prescribing information. New York, NY: Pfizer; 2013.

    Google Scholar 

  51. Voriconazole (VFend®) prescribing information. New York NY: Pfizer; 2015.

    Google Scholar 

  52. Posaconazole (Noxafil®) prescribing information. Whitehouse Station, NJ: Merck; 2014.

    Google Scholar 

  53. Bernardo VA, Cross SJ, Crews KR. Posaconazole therapeutic drug monitoring in pediatric patients and young adults with cancer. Ann Pharmacother. 2013;47:976–83.

    Article  PubMed  PubMed Central  Google Scholar 

  54. Isavuconazonium (Cresemba®) prescribing information. Northbrook, IL: Astellas; 2015.

    Google Scholar 

  55. Caspofungin (Cancidas®) prescribing information. Whitehouse Station, NJ: Merck; 2017.

    Google Scholar 

  56. Micafungin (Mycamine®) prescribing information. Northbrook, IL: Atellas; 2016.

    Google Scholar 

  57. Amphotericin b liposome (Ambisome®) prescribing information. Northbrook, IL: Astellas, 2012.

    Google Scholar 

  58. Mehta J, Blake J, Craddock C. Comparative efficacy of amphotericin b lipid complex and liposomal amphotericin b for the treatment of invasive fungal infections in HSCT recipients and other immunocompromised patient populations with hematological malignancies: a critical review. Open Transplant J. 2011;5:23–9.

    Article  CAS  Google Scholar 

  59. Jancel T, Penzak SR. Antiviral therapy in patients with hematologic malignancies, transplantation, and aplastic anemia. Semin Hematol. 2009;46:230–47.

    Article  CAS  PubMed  Google Scholar 

  60. Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant. 2009;15(10):1143–238.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Acyclovir (Zovirax®) prescribing information. Research Triangle Park, NC: GlaxoSmithKline; 2005.

    Google Scholar 

  62. Acyclovir sodium for injection (Zovirax®) prescribing information. Research Triangle Park, NC: GlaxoSmithKline; 2003.

    Google Scholar 

  63. Valacyclovir (Valtrex®) prescribing information. Research Triangle Park, NC: GlaxoSmithKline; 2013.

    Google Scholar 

  64. Ganciclovir (Cytovene®-IV) prescribing information. Nutley, NJ: Roche Laboratories Inc; 2006.

    Google Scholar 

  65. Valganciclovir (Valcyte®) prescribing information. San Francisco, CA: Genentech, Inc; 2015.

    Google Scholar 

  66. Mofenson LM, Brady MT, Danner SP, et al. Guidelines for the prevention and treatment of opportunistic infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institute of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics. MMWR Recomm Rep. 2009;58(RR-11):1–166.

    PubMed  PubMed Central  Google Scholar 

  67. Foscarnet prescribing information. Lake Forest, IL: Hospira, Inc; 2015.

    Google Scholar 

  68. Caruso Brown AE, Cohen MN, Tong S, Braverman RS, Rooney JF, Giller R, et al. Pharmacokinetics and safety of intravenous cidofovir for life-threatening viral infections in pediatric hematopoietic stem cell transplant recipients. Antimicrob Agents Chemother. 2015;59:3718–25.

    Article  PubMed  PubMed Central  Google Scholar 

  69. Yusuf U, Hale GA, Carr J, et al. Cidofovir for the treatment of adenoviral infection in pediatric hematopoietic stem cell transplant patients. Transplantation. 2006;81(10):1398–404.

    Article  CAS  PubMed  Google Scholar 

  70. Cidofovir (Vistide®) prescribing information. Foster City, CA: Gilead Sciences; 2000.

    Google Scholar 

  71. CSL Behring AG. CytoGam® (cytomegalovirus immune globulin intravenous (human)) package insert. Bern: CSL Behring AG; 2007.

    Google Scholar 

  72. Alexander BT, Hladnik LM, Augustin KM, et al. Use of cytomegalovirus intravenous immune globulin for the adjunctive treatment of cytomegalovirus in hematopoietic stem cell transplant patients. Pharmacotherapy. 2010;30(6):554–61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  73. Hughes WT, Kuhn S, Chaudhary S, et al. Successful chemoprophylaxis for Pneumocystis carinii pneumonitis. N Engl J Med. 1977;297:1419–26.

    Article  CAS  PubMed  Google Scholar 

  74. Centers for Disease Control and Prevention (CDC). Guidelines for the prevention and treatment of opportunistic infections among HIV-exposed and HIV-infected children. MMWR Recomm Rep. 2009;58(RR-11):1–166.

    Google Scholar 

  75. Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. J Pediatr. 2001;139(2):317–9.

    Article  CAS  PubMed  Google Scholar 

  76. Paap CM, Nahata MC. Trimethoprim/sulfamethoxazole dosing during renal dysfunction. Annals Pharmacother 199 Voeller D, Kovacs J, Andrawis V, et al. Interaction of Pneumocystis carinii dihydropteroate synthase with sulfonamides and diaminodiphe- nylsulfone (dapsone). J Infect Dis. 1994;169:456–9.

    Article  Google Scholar 

  77. Huges WT. Use of dapsone in the prevention and treatment of pneumocystis carinii pneumonia: a review. CID. 1998;27:191–204.

    Article  Google Scholar 

  78. Rolan PE, Mercer AJ, Tate E, Benjamin I, Posner J. Disposition of atovaquone in humans. Antimicrob Agents Chemother. 1997;41:1319–21.

    CAS  PubMed  PubMed Central  Google Scholar 

  79. Artymowicz RJ, James VE. Atovaquone: a new antipneumocystis agent. Clin Pharm. 1993;12(8):563–70.

    CAS  PubMed  Google Scholar 

  80. Ondansetron (Zofran®) prescribing information. Research Triangle Park, NC: Glaxo Smith Kline; 2014.

    Google Scholar 

  81. Dupuis LL, Boodhan S, Holdsworth M, et al. Guideline for the prevention of acute nausea and vomiting due to antineoplastic medication in pediatric cancer patients. Pediatr Blood Cancer. 2013;60:1073–82.

    Article  PubMed  Google Scholar 

  82. Ondansetron (Zofran®) product information. Dorval, QC: Novartis Pharmaceuticals Canada, Inc; 2016.

    Google Scholar 

  83. Granisetron hydrochloride (Kytril®) prescribing information. Nutley, NJ: Roche Laboratories Inc; 2009.

    Google Scholar 

  84. Granisetron transdermal system (Sancuso®) prescribing information. St. Paul, MN: ProStrakan Inc; 2015.

    Google Scholar 

  85. Palonosetron (Aloxi®) prescribing information. Woodcliff Lake, NJ: Eisai Inc; 2015.

    Google Scholar 

  86. Chlorpromazine prescribing information. Eatontown, NJ: West-ward Pharmaceuticals; 2012.

    Google Scholar 

  87. Van Hoff J, Olszewski D. Lorazepam for the control of chemotherapy-related nausea and vomiting in children. J Pediatr. 1988;113:146–9.

    Article  PubMed  Google Scholar 

  88. Lorazepam (Ativan®) prescribing information. Philadelphia, PA: Wyeth Pharmaceuticals, Inc; 2007.

    Google Scholar 

  89. Metoclopramide (Reglan ®) prescribing information. Deerfield, IL: Baxter Healthcare Corporation; 2010.

    Google Scholar 

  90. Emir S, Ertugut P, Vidinlisan S. Comparison of granisetron plus dexamethasone versus an antiemetic cocktail containing midazolam and diphenhydramine for chemotherapy induced nausea and vomiting in children. Indian J Med Paediatr Oncol. 2013;34(4):270–3.

    Article  PubMed  PubMed Central  Google Scholar 

  91. Diphenhydramine prescribing information. Greenville, SC: Pharmaceutical Associates, Inc; 2008.

    Google Scholar 

  92. Promethazine prescribing information. Byran, OH: Sun Pharmaceutical Industries, Inc; 2015.

    Google Scholar 

  93. Navari RM, Einhorn LH, Loehrer PJ, et al. A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy induced nausea and vomiting: a Hoosier oncology group study. Support Care Cancer. 2007;15:1285–91.

    Article  PubMed  Google Scholar 

  94. Olanzapine (Zyprexa®) prescribing information. Indianapolis, IN: Eli Lilly and Company; 2015.

    Google Scholar 

  95. Flank J, Thackray J, Nielson D, et al. Olanzapine for treatment and prevention of acute chemotherapy-induced vomiting in children: a retrospective, multi-center review. Pediatr Blood Cancer. 2015;62(3):496–501.

    Article  CAS  PubMed  Google Scholar 

  96. Elder JJ, Knodere HM. Characterization of dronabinol usage in a pediatric oncology population. J Pediatr Pharmacol Ther. 2015;20(6):462–7.

    PubMed  PubMed Central  Google Scholar 

  97. Dronabinol (Marinol ®) prescribing information. Marietta, GA: Solvay Pharmaceuticals, Inc; 2004.

    Google Scholar 

  98. Nabilone (Cesamet®) prescribing information. Quebec: Meda Pharmaceuticals; 2013.

    Google Scholar 

  99. Scopolamine (Transderm Scop®) patch prescribing information. Princeton, NJ: Sandoz, Inc; 2014.

    Google Scholar 

  100. Kang HJ, Loftus S, Taylor A, et al. Aprepitant for the prevention of chemotherapy-induced nausea and vomiting in children: a randomized double-blind, phase 3 trial. Lancet Oncol. 2015;16:385–94.

    Article  CAS  PubMed  Google Scholar 

  101. Choi MR, Jilrd C, Seibel NL. Aprepitant use in children, adolescents, and young adults for the control of chemotherapy-induced nausea and vomiting (CINV). J Pediatr Hematol Oncol. 2010;32:e268–71.

    Article  PubMed  Google Scholar 

  102. Berde CB, Sethna NF. Analgesics for the treatment of pain in children. NEJM. 2002;347(14):1094–103.

    Article  CAS  PubMed  Google Scholar 

  103. Chow EJ, Wong K, Lee SJ, et al. Late cardiovascular complications after hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2014;20(6):794–800.

    Article  PubMed  PubMed Central  Google Scholar 

  104. Flynn JT. Management of hypertension in the young: role of antihypertensive medications. J Cardiovasc Pharmacol. 2011;58(2):111–20.

    Article  CAS  PubMed  Google Scholar 

  105. Horn DG, Trame MN, Hempel G. The management of hypertensive emergencies in children after stem cell transplantation. Int J Clin Pharm. 2011;33:165–76.

    Article  CAS  PubMed  Google Scholar 

  106. Ingelfinger JR. The child or adolescent with elevated blood pressure. NEJM. 2014;370(24):2316–25.

    Article  PubMed  Google Scholar 

  107. Kavey REW, Daniels SR, Flynn JT. Management of high blood pressure in children and adolescents. Cardiol Clin. 2010;28:597–607.

    Article  PubMed  Google Scholar 

  108. Lurbe E, Cifkova R, Cruickshank JK, et al. Management of high blood pressure in children and adolescents: recommendations of the European society of hypertension. J Hypertension. 2009;27:1719–42.

    Article  CAS  Google Scholar 

  109. National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics. 2004;114(2):555–76.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmacy, Penn State Milton S. Hershey Medical Center, Hershey, PA, USA

    Kevin M. Mulieri BS, PharmD, BCPPS

  2. Department of Pharmacy, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, USA

    Ashley Teusink-Cross PharmD, MBA, BCPS

  3. Department of Pharmacy, Akron Children’s Hospital, Akron, OH, USA

    JoEllen Weilnau PharmD

  4. Department of Pharmacy, Memorial Sloan Kettering Cancer Center, New York, NY, USA

    Krisoula Spatz PharmD, BCOP

  5. Department of Pediatrics, Monroe Carell Jr. Children’s Hospital at Vanderbilt University Medical Center, Nashville, TN, USA

    Katie S. Gatwood PharmD

Authors
  1. Kevin M. Mulieri BS, PharmD, BCPPS
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ashley Teusink-Cross PharmD, MBA, BCPS
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. JoEllen Weilnau PharmD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Krisoula Spatz PharmD, BCOP
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Katie S. Gatwood PharmD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kevin M. Mulieri BS, PharmD, BCPPS .

Editor information

Editors and Affiliations

  1. Division of Pediatric Oncology/Hematology, Penn State Health Children’s Hospital and Penn State Cancer Institute at the Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, USA

    Valerie I. Brown

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG

About this chapter

Cite this chapter

Mulieri, K.M., Teusink-Cross, A., Weilnau, J., Spatz, K., Gatwood, K.S. (2018). Medications Commonly Used in Pediatric HSCT. In: Brown, V. (eds) Hematopoietic Stem Cell Transplantation for the Pediatric Hematologist/Oncologist. Springer, Cham. https://doi.org/10.1007/978-3-319-63146-2_28

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-63146-2_28

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-63144-8

  • Online ISBN: 978-3-319-63146-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation